# the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

> **NCT04041362** · PHASE2 · WITHDRAWN · sponsor: **United BioPharma**

## Conditions studied

- HIV-1 Infection

## Interventions

- **BIOLOGICAL:** UB-421
- **OTHER:** Antiretroviral Therapy (ART)

## Key facts

- **NCT ID:** NCT04041362
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04
- **Primary completion:** 2020-12
- **Final completion:** 2021-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study will not be submitted to authority for IND application.
- **Last updated:** 2020-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04041362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04041362, "the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04041362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*